Hainan Huluwa Pharmaceutical Group Co Ltd - Class A

SHSE:605199 (China)   Class A
Â¥ 10.42 (-1.51%) Jun 13
43.42
P/B:
3.63
Market Cap:
Â¥ 4.17B ($ 574.98M)
Enterprise V:
Â¥ 5.27B ($ 726.69M)
Volume:
853.10K
Avg Vol (2M):
2.61M
Volume:
853.10K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd ( ) from 2020 to Jun 13 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hainan Huluwa Pharmaceutical Group stock (SHSE:605199) PE ratio as of Jun 13 2024 is 43.42. More Details

Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) PE Ratio (TTM) Chart

To

Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) PE Ratio (TTM) Historical Data

Total 952
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 11
Hainan Huluwa Pharmaceutical Group PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-13 43.4 2024-04-03 52.4
2024-06-12 44.1 2024-04-02 52.0
2024-06-11 43.3 2024-04-01 52.5
2024-06-07 43.0 2024-03-29 51.3
2024-06-06 42.2 2024-03-28 50.8
2024-06-05 44.0 2024-03-27 45.6
2024-06-04 45.2 2024-03-26 45.7
2024-06-03 45.2 2024-03-25 45.6
2024-05-31 46.4 2024-03-22 47.4
2024-05-30 46.2 2024-03-21 48.6
2024-05-29 46.3 2024-03-20 48.7
2024-05-28 46.5 2024-03-19 48.4
2024-05-27 47.0 2024-03-18 48.6
2024-05-24 47.1 2024-03-15 47.5
2024-05-23 47.1 2024-03-14 47.4
2024-05-22 48.3 2024-03-13 47.0
2024-05-21 48.3 2024-03-12 47.9
2024-05-20 49.3 2024-03-11 46.5
2024-05-17 49.3 2024-03-08 45.4
2024-05-16 49.2 2024-03-07 45.0
2024-05-15 49.7 2024-03-06 45.9
2024-05-14 50.1 2024-03-05 46.3
2024-05-13 49.6 2024-03-04 47.8
2024-05-10 50.5 2024-03-01 45.9
2024-05-09 51.8 2024-02-29 45.8
2024-05-08 51.0 2024-02-28 44.6
2024-05-07 50.8 2024-02-27 47.0
2024-05-06 50.5 2024-02-26 46.1
2024-04-30 48.7 2024-02-23 45.3
2024-04-29 48.2 2024-02-22 44.5
2024-04-26 46.9 2024-02-21 43.4
2024-04-25 46.3 2024-02-20 43.9
2024-04-24 46.3 2024-02-19 42.7
2024-04-23 46.3 2024-02-08 40.7
2024-04-22 45.7 2024-02-07 37.6
2024-04-19 45.4 2024-02-06 39.4
2024-04-18 47.2 2024-02-05 37.9
2024-04-17 46.3 2024-02-02 42.1
2024-04-16 44.3 2024-02-01 44.9
2024-04-15 46.9 2024-01-31 45.5
2024-04-12 48.7 2024-01-30 47.9
2024-04-11 49.5 2024-01-29 49.6
2024-04-10 50.1 2024-01-26 51.4
2024-04-09 51.6 2024-01-25 50.9
2024-04-08 50.3 2024-01-24 48.7

Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.